Daytrana® (methylphenidate transdermal)  
Effective 02/20/19

<table>
<thead>
<tr>
<th>Plan</th>
<th>Benefit</th>
<th>Program Type</th>
</tr>
</thead>
<tbody>
<tr>
<td>☒ MassHealth</td>
<td>☒ Pharmacy Benefit</td>
<td>☒ Prior Authorization</td>
</tr>
<tr>
<td>□ Commercial/Exchange</td>
<td>□ Medical Benefit (NLX)</td>
<td>□ Quantity Limit</td>
</tr>
<tr>
<td></td>
<td></td>
<td>□ Step Therapy</td>
</tr>
</tbody>
</table>

**Specialty Limitations:** N/A

**Specialty Medications**

- **All Plans**: Phone: 866-814-5506 | Fax: 866-249-6155

**Non-Specialty Medications**

- **MassHealth**: Phone: 877-433-7643 | Fax: 866-255-7569
- **Commercial**: Phone: 800-294-5979 | Fax: 888-836-0730
- **Exchange**: Phone: 855-582-2022 | Fax: 855-245-2134

**Medical Specialty Medications (NLX)**

- **All Plans**: Phone: 844-345-2803 | Fax: 844-851-0882

**Contact Information**

**Exceptions:** N/A

**Overview**

Daytrana is a CNS stimulant indicated for the treatment of Attention Deficit Hyperactivity Disorder (ADHD).

**Coverage Guidelines**

Approval will be granted if the member meets the following criteria:

1. Member has a diagnosis of attention deficit hyperactivity disorder (ADHD) or autism spectrum disorder (ASD) **AND**
2. Member has an inability to swallow tablets/capsules (i.e. swallowing disorder, dysphagia) **OR**
3. Prescriber has provided documentation of an inadequate response, adverse reaction, or contraindication to Concerta® (methylphenidate extended-release) **AND**
4. Prescriber has provided documentation of an inadequate response, adverse reaction, or contraindication to Focalin XR® (dexamethasone extended-release)

*Please note: Additional criteria may apply for members under the age of 18. Please refer to the MassHealth Pediatric Behavioral Health Medication Initiative guideline for criteria.*

**Continuation of Therapy**

Reauthorization require documentation by prescriber that indicates a positive response to therapy.

**Limitations**

1. Approvals will be granted for up to 1 year
2. The following quantity limits apply:
Daytrana patch 10 mg/9hr transdermal | 30 patches per 30 days
Daytrana patch 15 mg/9hr transdermal | 30 patches per 30 days
Daytrana patch 20 mg/9hr transdermal | 30 patches per 30 days
Daytrana patch 30 mg/9hr transdermal | 30 patches per 30 days

Appendix:
Adverse reactions/contraindications to stimulants include but are not limited to weight loss or failure to gain weight, insomnia, agitation, increased anger and aggression, tic disorder, seizures w/ ADHD, traumatic brain injury w/ ADHD (trial of both a methylphenidate product and amphetamine product is required for approval), symptomatic heart disease in children (tachycardia or hypertension), symptomatic heart disease in adults (there should be at least 1 failed trial of another non-stimulant medication that may be used for ADHD such as bupropion.)

References
1. Daytrana Package Insert, Shire Pharmaceuticals, LR 2010

Review History
03/01/18 – Implemented (adopted MH RS)
02/20/19 – Reviewed P&T Mtg

Disclaimer
AllWays Health Partners complies with applicable federal civil rights laws and does not discriminate or exclude people on the basis of race, color, national origin, age, disability, or sex.